MarketPulse

CRISPR gene editing

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics Advances Gene-Editing Platform With First Approved Therapy

CRISPR Therapeutics gains FDA approval for Casgevy, its first gene-editing therapy for rare blood disorders, validating the platform with multiple pipeline candidates in development.
CRSPFDA approvalclinical trials
The Motley FoolThe Motley Fool··Adria Cimino

CRISPR Therapeutics Poised for Growth on Casgevy Momentum and Pipeline Expansion

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.
VRTXCRSPFDA approvalclinical trials